ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment

Organogenesis is seeking approval for ReNu in knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.
Global stock market chart and trading board - stock photo
Representative image of stock market chart on a glowing particle world map and trading board. (Photo by Yuichiro Chino/Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Published Apr 06, 2026   |   5:55 PM EDT
Share
·
Add us onAdd us on Google

Shares of Organogenesis Holdings Inc. (ORGO) jumped 7% after hours on Monday after the company said that it met with the U.S. Food and Drug Administration (FDA), and now plans to initiate seeking approval for its experimental treatment ReNu before the end of December.

The company is seeking approval for ReNu in the treatment of knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.

ReNu is a cryopreserved, amniotic suspension allograft. It provides anti-inflammatory, growth factor, and cellular components, offering a non-surgical alternative to reduce inflammation, alleviate pain, and enhance joint function.

The company decided to initiate a rolling application for ReNu following the completion of a meeting with the FDA.

Get updates to this developing story directly on Stocktwits.

Follow on Google News
Read about our editorial guidelines and ethics policy